General
Preferred name
Orforglipron
Synonyms
LY3502970 ()
GLP-1 receptor agonist 1 ()
ORFORGLIPRON CALCIUM ()
LY-3502970 ()
LY3502970 HEMICALCIUM ()
Orforglipron hemicalcium ()
LY-3502970 HEMICALCIUM ()
P&D ID
PD102109
CAS
2212020-52-3
Tags
available
drug candidate
Drug Status
investigational
Max Phase
1.0
3.0
Drug indication
Obesity
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Oforglipron (LY3502970) is an oral, nonpeptide glucagon-like peptide-1 receptor (GLP-1R) agonist that was developed as a potential antidiabetic medication . It is a partial agonist (relative to native GLP-1), that biases GLP-1R signalling towards G protein activation and is devoid of β-arrestin recruitment activity. (GtoPdb)
DESCRIPTION Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete[1].
PRICE 1494
DESCRIPTION Orforglipron (LY3502970; GLP-1 receptor agonist 1) is an orally available glucagon-like peptide (GLP-1) receptor agonist for the study of obesity and type 1 diabetes in adults. (TargetMol Bioactive Compound Library)
Compound Sets
8
Cayman Chemical Bioactives
DrugBank
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
TargetMol Bioactive Compound Library
External IDs
13
Properties
(calculated by RDKit )
Molecular Weight
882.38
Hydrogen Bond Acceptors
13
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
11
Aromatic Ring Count
8
cLogP
7.44
TPSA
155.93
Fraction CSP3
0.38
Chiral centers
4.0
Largest ring
6.0
QED
0.17
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Member status
member
Target
GCGR
GLP-1
Source data